https://www.tysabri.com/
TYSABRI® (natalizumab) | Official Patient Website
Read about TYSABRI® (natalizumab), an infusion treatment option for adults with relapsing MS. See full Prescribing Info, including Boxed Warning.
natalizumabofficialpatient
https://www.goodrx.com/tyruko/what-is
Tyruko (natalizumab): Uses, Side Effects, Dosage & Reviews
Learn about Tyruko (natalizumab) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives.
side effectstyrukonatalizumabusesdosage
https://www.epo.org/de/boards-of-appeal/decisions/t172232eu1
T 2232/17 (Natalizumab for diseases treatable with steroids/BIOGEN) vom 24.02.2021
https://pmc.ncbi.nlm.nih.gov/articles/PMC6513248/
Natalizumab for induction of remission in Crohn's disease - PMC
This systematic review update summarizes the current evidence on the use of natalizumab for induction of remission in Crohn's disease (CD). To determine the...
crohn s diseasenatalizumabinductionremissionpmc
https://www.cochrane.org/de/evidence/CD015123_what-are-benefits-and-risks-natalizumab-ntz-people-multiple-sclerosis-ms
Was sind die Vorteile und Risiken von Natalizumab bei Multipler Sklerose? | Cochrane
was sind die vorteile
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-natalizumab-marketed-tysabri
Information on Natalizumab (marketed as Tysabri) | FDA
Information on Natalizumab (marketed as Tysabri)
information onnatalizumabmarketedtysabrifda
https://www.epo.org/en/boards-of-appeal/decisions/t231253eu1
T 1253/23 (Immune response to natalizumab/BIOGEN) of 16.12.2025
immune response
https://www.prweb.com/releases/abreos-biosciences-launches-laboratory-developed-test-for-precision-dose-monitoring-of-natalizumab-tysabri--840497137.html
Abreos Biosciences Launches Laboratory Developed Test for Precision Dose Monitoring of Natalizumab...
/PRNewswire-PRWeb/ -- Abreos Biosciences, a San Diego-based biotech company and leader in the precision dosing of biological therapeutics, is pleased to...
laboratory developed test
https://www.epo.org/fr/boards-of-appeal/decisions/t172232eu1
T 2232/17 (Natalizumab for diseases treatable with steroids/BIOGEN) du 24.02.2021
https://www.cochrane.org/ms/evidence/CD006097_natalizumab-treatment-active-crohns-disease
Natalizumab untuk rawatan penyakit Crohn aktif. | Cochrane
natalizumabuntukrawatanpenyakitcrohn
https://www.rti.org/publication/cost-effectiveness-natalizumab-vs-fingolimod-treatment-relapsing-remitting-multiple-sclerosis
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple...
Objective:To assess the cost-effectiveness of natalizumab vs fingolimod over 2 years in relapsing-remitting multiple sclerosis (RRMS) patients and patients...
cost effectiveness
https://www.cochrane.org/evidence/CD006097_natalizumab-treatment-active-crohns-disease
Natalizumab for treatment of active Crohn's disease | Cochrane
crohn s diseasenatalizumabtreatmentactivecochrane
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1414304/full
Frontiers | Comparative immunogenicity assessment of biosimilar natalizumab to its reference...
BackgroundBiosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms...
frontierscomparativeimmunogenicityassessmentbiosimilar